Bicalutamide 150 mg: Practical prescribing in patients with early prostate cancer

被引：2

作者：

Anderson, J ^{[1
]}

机构：

[1] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England

来源：

BJU INTERNATIONAL | 2004年 / 94卷 / 06期

关键词：

D O I：

10.1111/j.1464-410X.2004.05066.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：758 / 759

页数：2

共 50 条

[21] Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer - Editorial comment
Hammerer, PG
EUROPEAN UROLOGY, 2003, 44 (05) : 517 - 518
[22] Comparative Study Evaluating Safety and Efficacy of Bicalutamide (150 mg) Monotherapy versus Orchidectomy and Bicalutamide (50 mg) in the Treatment of Locally Advanced/Metastatic Prostate Cancer
Agnihotri, Laxmi
Gupta, Money
Mandial, Vishal
Kayastha, Anil
INTERNATIONAL JOURNAL OF SCIENTIFIC STUDY, 2016, 3 (12) : 18 - 22
[23] Adjuvant bicalutamide for early prostate cancer: an update
Cora N Sternberg
Nature Clinical Practice Urology, 2006, 3 : 408 - 409
[24] The bicalutamide Early Prostate Cancer Program: Demography
See, WA
McLeod, D
Iversen, P
Wirth, M
UROLOGIC ONCOLOGY, 2001, 6 (02): : 43 - 47
[25] Bicalutamide - In early-stage prostate cancer
Carswell, CI
Figgitt, DP
DRUGS, 2002, 62 (17) : 2471 - 2479
[26] Adjuvant bicalutamide for early prostate cancer: an update
Sternberg, Cora N.
NATURE CLINICAL PRACTICE UROLOGY, 2006, 3 (08): : 408 - 409
[27] New analysis shows that bicalutamide 150 mg as adjuvant to radical prostatectomy significantly increases progression-free survival in early prostate cancer
Klimberg, I
See, WA
Wirth, MP
McLeod, DG
Iversen, P
Soloway, M
Garside, L
JOURNAL OF UROLOGY, 2003, 169 (04): : 180 - 181
[28] Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression
Wirth, M
Tyrrell, C
Wallace, M
Delaere, KP
Sánchez-Chapado, M
Ramon, J
Hetherington, J
Pina, F
Heynes, CF
Borchers, TM
Morris, T
Stone, A
UROLOGY, 2001, 58 (02) : 146 - 150
[29] The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer
See, William A.
Tyrrell, Chris J.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2006, 132 (Suppl 1) : S7 - S16
[30] The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer
William A. See
Chris J. Tyrrell
Journal of Cancer Research and Clinical Oncology, 2006, 132 : 7 - 16

← 1 2 3 4 5 →